Clinical Trials Browser

Phase 1 × Anemia, Refractory, with Excess of Blasts × Bortezomib × Clear all

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00005064 2013-01-23

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Phase 1 Completed

30 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

PS-341 in Treating Patients With Hematologic Cancer

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome